Researchers identify novel cell type that leads to aggressive leukemia

by Josh Barney
Renin progenitors in the bone marrow with a lymphocyte pedigree (Brenin cells, shown in green) give rise to B-cell leukemia when the Notch pathway effector RBP-J is deleted. Credit: Maria Luisa S. Sequeira Lopez

Researchers at the University of Virginia School of Medicine have discovered a specific type of immune cell in the bone marrow of mice responsible for an aggressive, poorly understood form of leukemia.

The type of examined in the study proved particularly hardy and resourceful. After the cancer killed a mouse with the responsible mutation, the researchers placed the in a lab dish, where they continued to survive and even thrive.

"People have been trying to grow in culture, even from patients, and they require other factors to survive. But not these," said Dr. Maria Luisa S. Sequeira-Lopez, a researcher in the Division of Pediatric Nephrology.

Her co-researcher, Dr. Ariel Gomez, also of the Division of Pediatric Nephrology, marveled at the cells' ability to tolerate even the least hospitable conditions. "These are extremely aggressive in that they have developed a system to grow and survive no matter what," he said. "They have immortalized themselves."

The research provides important insight into B-cell leukemia, the causes of which are poorly understood, and could lead to new and better treatments.

In this case, the loss of a key cellular signaling molecule through mutation appears to trigger the development of the leukemia. More specifically, the loss of the signaling molecule caused a logjam in the production process of B cells, a type of white blood cell. The mutated cells then become cancerous.

The type of cell affected is a renin progenitor. Renin cells, which are also present in the kidney, have traditionally been associated with the control of blood pressure and fluid balance in the body. However, U.Va. investigators found that there are renin progenitors in the as well.

The role of bone marrow renin cells in the development of leukemia had been unknown, but the U.Va. researchers were able to determine that the leukemia originated in a special type of white blood cell, a B lymphocyte that expresses renin – a cell the group has dubbed "Brenin-cells." The researchers then went on to discover and describe the genetic and epigenetic events that lead to the leukemia.

Conventional wisdom is that leukemia arises when a genetic event occurs in a susceptible cell. Over the last decade, much knowledge has been gained regarding the genetic events that drive leukemia; the exact cell of origin, however, remains largely unknown. This study suggests that there may be subsets of cells at increased risk of developing leukemia.

The discovery means the researchers have many exciting avenues to explore. U.Va.  pediatrician Dr. Brian C. Belyea, the lead author of the paper outlining the findings, is investigating whether the findings will hold true in humans.

"We would now like to see if this is a relevant model of human disease," he said. "Our long-term goal is to identify cells at increased risk for leukemia in humans and ultimately develop strategies to monitor and eliminate these ."

More information: "Identification of renin progenitors in the mouse bone marrow that give rise to B-cell leukaemia." Brian C. Belyea, et al. Nature Communications 5, Article number: 3273 DOI: 10.1038/ncomms4273. Received 10 August 2013 Accepted 16 January 2014 Published 18 February 2014

add to favorites email to friend print save as pdf

Related Stories

Rare form of leukemia found to originate in stem cells

Feb 13, 2014

(Medical Xpress)—An international team of researchers working out of the University of Toronto has found that one type of rare leukemia appears to get its start in stem cells. In their paper published in ...

Common mutation is culprit in acute leukemia relapse

Mar 06, 2014

Harvard stem cell scientists have identified a mutation in human cases of acute lymphoblastic leukemia that likely drives relapse. The research, published in Cancer Cell, could translate into improved patien ...

Recommended for you

Bone loss drugs may help prevent endometrial cancer

7 hours ago

A new analysis suggests that women who use bisphosphonates—medications commonly used to treat osteoporosis and other bone conditions—have about half the risk of developing endometrial cancer as women who do not use the ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.